Intellectual property law
fromPatently-O
3 days agoThe Thin Margin Between "Generic Vascepa" and Active Inducement
The Supreme Court's hearing on Hikma v. Amarin focuses on patent inducement without needing a new legal doctrine.
The leading contender is Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, which asks whether a generic drug manufacturer that fully carves patented uses out of its FDA-approved label can nonetheless face induced infringement liability simply by calling its product a "generic version" of the brand-name drug or referencing publicly available information about the branded product's sales. The